Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Non-Current Deffered Revenue: 2019-2024

Historic Non-Current Deffered Revenue for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $51.8 million.

  • Silence Therapeutics' Non-Current Deffered Revenue rose 173.37% to $55.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.3 million, marking a year-over-year increase of 173.37%. This contributed to the annual value of $51.8 million for FY2024, which is 30.95% down from last year.
  • Silence Therapeutics' Non-Current Deffered Revenue amounted to $51.8 million in FY2024, which was down 30.95% from $75.0 million recorded in FY2023.
  • Over the past 5 years, Silence Therapeutics' Non-Current Deffered Revenue peaked at $99.8 million during FY2021, and registered a low of $51.8 million during FY2024.
  • Over the past 3 years, Silence Therapeutics' median Non-Current Deffered Revenue value was $75.0 million (recorded in 2023), while the average stood at $68.5 million.
  • In the last 5 years, Silence Therapeutics' Non-Current Deffered Revenue surged by 232.78% in 2020 and then slumped by 30.95% in 2024.
  • Silence Therapeutics' Non-Current Deffered Revenue (Yearly) stood at $65.9 million in 2020, then skyrocketed by 51.31% to $99.8 million in 2021, then decreased by 21.24% to $78.6 million in 2022, then declined by 4.54% to $75.0 million in 2023, then plummeted by 30.95% to $51.8 million in 2024.